Seventh Late-Stage Project Adds Neurology Deal for Lifecore Biomedical

Lifecore Biomedical has entered into a new agreement with a global pharmaceutical company to provide technical transfer and commercial manufacturing services for an injectable suspension product targeting neurological disorders. This partnership marks the company's seventh late-stage program win within a seven-month period, highlighting a significant expansion of its contract development and manufacturing organization (CDMO) pipeline. The deal underscores the pharmaceutical industry's growing demand for specialized U.S.-based manufacturing of high-viscosity and complex formulations.

Lifecore Biomedical, Inc. (NASDAQ: LFCR), a Chaska, Minnesota-based CDMO, announced on June 15, 2026, that it has secured a contract with an undisclosed global pharmaceutical firm. Under the agreement, Lifecore will manage the technical transfer and eventual commercial production of a high-viscosity injectable suspension intended for the treatment of neurological disorders. CEO Paul Josephs noted that the selection reflects industry confidence in the company’s technical expertise and quality track record, particularly regarding complex pharmaceutical products that require specialized manufacturing processes.

This agreement represents the seventh late-stage program Lifecore has added to its portfolio in the last seven months, continuing a period of rapid business development. The company recently saw a 12.37% increase in share price following a similar agreement for an ophthalmic injectable on June 2, 2026, and an 8.97% gain after a growth conference in May. These wins are critical for the firm as it seeks to offset recent financial headwinds, including a reported 34% year-over-year decline in Q1 2026 revenues, which totaled $23.2 million and led to a 3.88% dip in stock value. The company’s strategy focuses on leveraging its 40 years of expertise in hyaluronic acid and sterile fill-and-finish capabilities for syringes, vials, and cartridges.

While the commercial momentum is positive, the company continues to navigate complex regulatory and financial landscapes. A Form S-3 shelf registration dated September 22, 2025, remains in effect for the resale of up to 20,456,637 shares of common stock, including those from Series A Convertible Preferred Stock with a 7.5% PIK dividend and a conversion price of approximately $6.53. Additionally, the company previously disclosed an auditor’s adverse opinion regarding the effectiveness of its internal controls as of May 25, 2025. Nevertheless, the steady accumulation of late-stage contracts with multinational pharmaceutical partners suggests a robust market position for Lifecore’s specialized U.S. manufacturing operations, which are increasingly sought after for complex injectable formulations.